Can a simple test guide chemo for pancreatic cancer patients?

NCT ID NCT04472910

Ongoing Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a biomarker called GATA6 can help predict how well patients with resectable pancreatic cancer respond to chemotherapy before and after surgery. About 84 participants will provide tumor samples to measure GATA6 levels, then receive a standard chemo regimen. The goal is to see if GATA6 levels are linked to longer disease-free survival, which could lead to more personalized treatment choices in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE PANCREATIC CANCER

Contacts and locations

Locations

BC Cancer Agency Vancouver

Vancouver, British Columbia, Canada
Jewish General Hospital

Montreal, Quebec, Canada
Kingston Health Sciences Centre

Kingston, Ontario, Canada
London Health Sciences Centre

London, Ontario, Canada
Ottawa Hospital

Ottawa, Ontario, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2N9, Canada
Sunnybrook Hospital/Odette Cancer Centre

Toronto, Ontario, Canada
Unity Health (St. Joseph's and St. Michael's)

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.